These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38468814)

  • 1. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
    Wang L; Xu L; Han S; Zhu X
    Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
    Zhu C; Jiang X; Xiao H; Guan J
    Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
    Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
    Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p.
    Dong Y; Xu T; Zhong S; Wang B; Zhang H; Wang X; Wang P; Li G; Yang S
    Life Sci; 2019 Dec; 239():116984. PubMed ID: 31647948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
    Liu Y; Zhang Y; Li Q; Xu R; Huang N
    Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lung cancer.
    Chang F; Li J; Sun Q; Wei S; Song Y
    Bioengineered; 2022 Apr; 13(4):8806-8822. PubMed ID: 35287543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R; Liu H
    Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis
    Wu M; Jin MM; Cao XH; Zhao L; Li YH
    Curr Cancer Drug Targets; 2024; 24(4):445-454. PubMed ID: 37644752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
    Jia ZX; Zhang Z; Li Z; Li A; Xie YN; Wu HJ; Yang ZB; Zhang HM; Zhang XM
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2331-2343. PubMed ID: 33755971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circ_0110498 facilitates the cisplatin resistance of non-small cell lung cancer by mediating the miR-1287-5p/RBBP4 axis.
    Hao D; Li Y; Shi J; Jiang J
    Thorac Cancer; 2023 Mar; 14(7):662-672. PubMed ID: 36691322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circ_0004015 silencing represses cisplatin chemoresistance and tumor progression by reducing KLF8 in a miR-198-dependent manner in non-small cell lung cancer.
    Li Y; Yang X; Xiong X
    Genomics; 2022 Mar; 114(2):110294. PubMed ID: 35134495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).
    Wei D; Zeng J; Rong F; Xu Y; Wei R; Zou C
    Bioengineered; 2022 Mar; 13(3):5126-5140. PubMed ID: 35170372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.